Sponsor Dossier
Clinect
Sponsor Dossier for Clinect. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: CATAPRES
- Brand: FELODUR ER
- Brand: FLUORESCEIN
- Brand: HALDOL
- Brand: IBAVYR
- Brand: IMDUR
- Brand: IOPIDINE
- Brand: LARGACTIL
- Device (sponsor): Needle, subcutaneous injection/infusion port
- Device (sponsor): Infusion administration set, infusion pump
About
Clinect is an Australian Private Company with ABN 76 150 558 473, based in Victoria and currently active.
Portfolio
Clinect has 21 brands on the ARTG, of which 21 are indexable and 21 carry a Product Information document. 11 brands are PBS-listed, 2 have a PBAC outcome on record, and 2 have an AusPAR on record. Notable brands include CATAPRES, FELODUR ER, FLUORESCEIN, HALDOL, IBAVYR, IMDUR, IOPIDINE, LARGACTIL, METARAMINOL TORBAY, MONODUR, NEULACTIL, PERSANTIN.
Therapeutic focus
— Cardiology: 8 brands — Psychiatry: 3 brands — Neurology: 3 brands — Ophthalmology: 2 brands — Haematology: 1 brand — Endocrinology: 1 brand — Rare Disease: 1 brand — Infectious Disease: 1 brand — Other: 1 brand
PBS footprint
11 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2023-11-01, across 2 brands with a PBAC outcome on record. The latest AusPAR is 2025-02-06, across 2 brands with an AusPAR on record.